Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Baum talks about potential label expansions for Sutent and the early stage pipeline. Plus, Oncology Commercial Head Ayers weighs in with Pfizer’s take on licensing and acquisitions in the therapeutic area.
You may also be interested in...
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.
Pfizer Picks Second TRL9 Candidate From Coley For Development In Oncology
Company will continue investigating compounds despite a recent setback with its Toll-like receptor program in lung cancer.